S
TARS icon

SignatureFD’s Tarsus Pharmaceuticals TARS Stock Holding History

SignatureFD’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7
Closed -$573 – 3581
2025
Q4 		$573 Buy
+7
New +$523 ﹤0.01% 3218
2025
Q3 		– Sell
-23
Closed -$932 – 3477
2025
Q2 		$932 Buy
23
+8
+53% +$360 ﹤0.01% 3036
2025
Q1 		$771 Buy
+15
New +$741 ﹤0.01% 3099
2023
Q3 		– Sell
-572
Closed -$10.3K – 3303
2023
Q2 		$10.3K Buy
+572
New +$9.09K ﹤0.01% 2223
2023
Q1 		– Sell
-13
Closed -$191 – 3374
2022
Q4 		$191 Sell
13
-211
-94% -$3.49K ﹤0.01% 3192
2022
Q3 		$4K Buy
+224
New +$3.56K ﹤0.01% 2568
2021
Q3 		– Sell
-27
Closed -$1K – 3205
2021
Q2 		$1K Buy
+27
New +$843 ﹤0.01% 2833

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SignatureFD's TARS Position: Q1 2026 in Review

SignatureFD sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 7 shares — an estimated $573 sold.

SignatureFD first reported a position in TARS in Q2 2021 and held it in 7 quarters. The position peaked at $10.3K in Q2 2023. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • SignatureFD reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SignatureFD sold 7 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $573.
  • SignatureFD first reported a position in Tarsus Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • SignatureFD's Tarsus Pharmaceuticals position peaked at $10.3K in Q2 2023.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.